HLA-DRB1 and rheumatoid arthritis: However, no significant associations were observed between SE with Val11 or HLA-DRB1 Val11 and good responders in seropositive RA patients treated with TNFi (OR = 0.82 [0.48–1.41], P = 0.47, OR = 0.86 [0.49–1.51], P = 0.60, respectively) (Table 3).